Brind.

Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.

5 reports, 1 independent Updated Aug 28

Gone quiet

Reports: 5
Developments: 2
Repetition: 60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.

Who's involved

What this event is mainly about

Summit Therapeutics Pfizer Merck

How it developed

Newest first. Tap a step to see who reported it.

Jul 7Summit Therapeutics acquired Akeso license; ivonescimab showed better results than Keytruda.
Jul 2ivonescimab shows better PFS for EGFRmut NSCLC

Keep exploring

The entities involved

Summit Therapeutics
biopharmaceutical company

Nothing else this week.
Pfizer
American multinational pharmaceutical and biotechnology corporation
- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Mon 05:00
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
Merck
public company in Indonesia
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13

Related events

Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Jun 8

Coverage

Newest first; wire copies grouped

Aug 1scmp.com
Jul 7Unknown outlet
Jul 4Unknown outlet
Jul 2Unknown outlet

1 more outlet ran the same wire story

Aug 28chinaeconomicreview.com